Main finding: Ranibizumab 0.5 mg administered according to a treat-and-extend was statistically noninferior and clinically comparable with a monthly regimen in improving visual acuity from baseline to the end of study
Purpose: To evaluate the efficacy and safety of ranibizumab 0.5 mg treat-and-extend versus monthly regimens in patients with CNV secondary to AMD
Study type: Randomized controlled Trial
Condition: Neovascular AMD
Participants: treatment-naïve active subfoveal CNV secondary to AMD
n=650
Intervention:
Group 1: Ranibizumab 0.5mg treat-and-extend regimen
Group 2: Ranibizumab 0.5mg monthly regimen
The T&E regimen was noninferior to the monthly regimen, with mean BCVA change from baseline of 6.2 versus 8.1 letters respectively.
Fewer injections were required in patients receiving the T&E (8.7) versus monthly (11.1) regimen.
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive